Genocea Biosciences (GNCA) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Provides Third Quarter 2020 Corporate Update
October 29, 2020 7:01 AM EDTInitiated GEN-011 Phase1/2a clinical trial
Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy
Closed financing with net proceeds of $74.5 million
Upcoming presentations at SITC 2020 Virtual Conference on GEN-009, InhibigensTM and GEN-011
Conference call today at 8:30 a.m. EDT
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) --... More
